Evan S. Dellon, MD, MPH | Division of ...

Dr. Evan Dellon, MD

Claim this profile

University Of North Carolina At Chapel Hill

Studies Eosinophilic Esophagitis
Studies Gastrointestinal Bleeding
6 reported clinical trials
5 drugs studied

Affiliated Hospitals

Image of trial facility.
University Of North Carolina At Chapel Hill
Image of trial facility.
The University Of North Carolina At Chapel Hill

Clinical Trials Evan Dellon, MD is currently running

Image of trial facility.

Dupilumab

for Eosinophilic Esophagitis

The purpose of this research study is to determine how well an FDA-approved drug, dupilumab, works to treat patients with severe strictures and active Eosinophilic Esophagitis (EoE). This is an open-label study, meaning everyone in the study will receive dupilumab. Participants will have a screening visit where they will complete surveys and undergo an endoscopy (EGD). Blood and biopsies (small tissue samples) will also be collected. If eligible and enrolled into the study, participants will receive weekly subcutaneous (under the skin) injections of dupilumab for 52 weeks (one year). The first dose of dupilumab will be administered in the clinic at the enrollment visit (day 0) and participants (or their caregivers) will receive training on how to self-administer the remaining doses. Participants will return for study visits every at weeks 4, 8, 12, 18, 24, 30, 36, 44, and 52. During these visits, vital signs (temperature, heart rate, etc.) will be collected and participants will complete surveys. During visits at week 12, 24, and 52, blood will be collected and an endoscopy with biopsy will be performed. At 64 weeks (12 weeks after the last dose of dupilumab), participants assigned female at birth (AFAB) may be asked to come to the clinic for a urine pregnancy test.
Recruiting3 awards Phase 4

More about Evan Dellon, MD

Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 1 Active Clinical Trial
Treatments Evan Dellon, MD has experience with
  • Placebo
  • Dupilumab
  • CC-93538
  • Immune Directed Individualized Elimination Therapy (iDIET) Study
  • Mepolizumab
Breakdown of trials Evan Dellon, MD has run
Eosinophilic Esophagitis
Gastrointestinal Bleeding
Eosinophilic esophagitis
Stenosis
Lupus Enteritis

Other Doctors you might be interested in

Benny Joyner, MD, MPHThe University of North Carolina at Chapel Hill
Patrick Thompson, M.D.University of North Carolina Lineberger Comprehensive Cancer Center
Laura Hanson, MDUniversity of North Carolina at Chapel Hill

Frequently asked questions

Do I need insurance to participate in a trial?
What does Evan Dellon, MD specialize in?
Is Evan Dellon, MD currently recruiting for clinical trials?
Are there any treatments that Evan Dellon, MD has studied deeply?
What is the best way to schedule an appointment with Evan Dellon, MD?
What is the office address of Evan Dellon, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security